Literature DB >> 26549283

Dramatic Response to Cardiac Resynchronization Therapy With AV Delay Optimization in Narrow QRS Heart Failure.

Rikitake Kogawa1, Toshiko Nakai, Yukitoshi Ikeya, Hiroaki Mano, Kazumasa Sonoda, Naoko Sasaki, Kazuki Iso, Yasuo Okumura, Kimie Ohkubo, Satoshi Kunimoto, Ichiro Watanabe, Atsushi Hirayama.   

Abstract

Cardiac resynchronization therapy (CRT) has been shown to be effective for heart failure. However, as outlined in the AHA/ACC/HRS Appropriate Use Criteria, CRT is not strongly recommended for patients with a narrow QRS complex. We describe a case of dilated cardiomyopathy and narrow QRS complex in which we obtained a dramatic response to CRT by optimizing the atrioventricular (AV) delay. The patient was a 61-year-old man with intractable heart failure. Echocardiography showed a low ejection fraction of 22% but no dyssynchrony. Because he had been hospitalized many times for congestive heart failure despite β-blocker and diuretic treatment, we decided to use CRT. However, after implantation of the CRT device, the QRS complex widened abnormally, and his symptoms worsened. He was re-admitted 2 months after CRT implantation. We examined the pacemaker status and optimized the AV delay to obtain a "narrow" QRS complex. The patient's condition improved dramatically after the AV delay optimization. His clinical status has been good, and there has been no subsequent hospitalization. Our case points to the effectiveness of CRT in patients with a narrow QRS complex and to the importance of AV optimization for successful CRT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26549283     DOI: 10.1536/ihj.15-126

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  1 in total

1.  Narrower QRS may be enough to respond to cardiac resynchronization therapy in lightweight patients.

Authors:  Toshiko Nakai; Hiroaki Mano; Yukitoshi Ikeya; Yoshihiro Aizawa; Sayaka Kurokawa; Kimie Ohkubo; Koichi Nagashima; Ichiro Watanabe; Yasuo Okumura
Journal:  Heart Vessels       Date:  2019-11-27       Impact factor: 2.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.